PARP inhibitors can play a significant role in the first-line setting for patients with advanced ovarian cancer.
CU Anschutz
Anschutz Cancer Pavilion
1665 North Aurora Court
2004
Aurora, CO 80045
Clinical Commentary: Managing Adverse Events From PARP Inhibitors in Advanced Ovarian Cancer
minute read
by Targeted Oncology | September 30, 2022
